Clinical Trial

Human Infection Study of H3N2 Influenza in Healthy Adults

Study acronym: FluCHIM
Completed
View on ClinicalTrials.gov →
Summary
This study will examine how the immune system responds to a flu virus (H3N2) during and after infection in health adults aged between 18 and 50 while in an inpatient facility. The study uses a specific flu virus called the H3N2 influenza challenge virus, that was produced specifically for use in clinical research in controlled conditions. From a previous study, mild to moderate symptoms are expected. This is the first time that a flu challenge study has been undertaken in Australia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-06; most recent amendment 2026-04-29.
Status change: Active, Not Recruiting → Completed 2026-04-29
Status change: Recruiting → Active, Not Recruiting 2025-06-10
Trial Details
NCT Number NCT06972810
Lead Sponsor University of Melbourne
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), World Health Organization
Conditions Influenza
Enrollment 11 participants
Start Date 2025-05-05
Primary Completion 2025-11-26 (estimated)
Study Completion 2025-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-30